RENOVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RENOVA (RENOVA).
Renova (tretinoin) is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ). It modulates gene expression, increasing collagen synthesis, reducing collagen breakdown via inhibition of matrix metalloproteinases, and promoting epidermal cell turnover and proliferation.
| Metabolism | Primarily hepatic via cytochrome P450 (CYP) enzymes, including CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Tretinoin is metabolized to 4-oxo-all-trans-retinoic acid and other polar metabolites. |
| Excretion | Renal (approximately 99% as unchanged drug), biliary/fecal (<1%) |
| Half-life | Terminal half-life is 2-4 hours in patients with normal renal function; prolonged to 18-24 hours in end-stage renal disease |
| Protein binding | 88% bound primarily to albumin |
| Volume of Distribution | 0.5-0.8 L/kg, indicating distribution into total body water |
| Bioavailability | Oral: 38-58% (significant first-pass metabolism); Sublingual: approximately 75%; Intranasal: 30-50% |
| Onset of Action | Oral: 30-60 minutes; Sublingual: 5-10 minutes; Intravenous: immediate |
| Duration of Action | Oral: 6-8 hours; Sublingual: 2-4 hours; Intravenous: 2-3 hours. Clinical effect correlates with plasma concentration. |
Apply a thin layer to affected area once daily at bedtime. Use only fingertips to apply (0.1% cream).
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not indicated for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of skin irritation and thinner skin in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RENOVA (RENOVA).
| Breastfeeding | It is unknown if tretinoin is excreted in human breast milk after topical application. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is not available. |
| Teratogenic Risk | Tretinoin (the active ingredient in Renova) is contraindicated in pregnancy due to high teratogenic risk. It is classified as FDA Pregnancy Category D (positive evidence of human fetal risk). Oral retinoids are known to cause CNS, craniofacial, cardiovascular, and thymic abnormalities in the first trimester. Topical application may have lower systemic absorption, but due to lack of adequate studies and potential for fetal harm, use is not recommended in pregnant women. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to tretinoin or any component of the formulation.","Active sunburn, eczematous, or otherwise compromised skin.","Concurrent use with other retinoids (e.g., isotretinoin) due to additive toxicity."]
| Precautions | ["Avoid excessive exposure to sunlight or other UV irradiation; use sun protection measures.","May cause severe skin irritation, erythema, peeling, and photosensitivity.","Not to be used in pregnancy (Pregnancy Category C, but caution as retinoids are teratogenic in animal studies).","Avoid use on eczematous, sunburned, or broken skin.","Concomitant use with other topical irritants (e.g., medicated soaps, astringents) may increase irritation.","Temporary worsening of acne (acne flare) may occur during initial use."] |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring is mandated for topical tretinoin use. However, if accidental oral ingestion occurs or if used despite contraindication, fetal ultrasound should be considered to assess for congenital anomalies. |
| Fertility Effects | There are no well-controlled studies on the effect of topical tretinoin on human fertility. Animal studies with oral retinoids have shown effects on fertility, but topically applied tretinoin is unlikely to impact fertility due to low systemic absorption. |